Klivarin

Klivarin: direct-acting anticoagulant for the prevention of thrombosis and embolism

Klivarin is a drug belonging to the group of direct-acting anticoagulants. The active ingredient is reviparin sodium, the drug is produced in the form of an injection solution of 1750 units. Klivarin is produced by Knoll AG in Germany and is used for the prevention of thrombosis and embolism.

Indications for use of Clivarin

Klivarin is used to prevent thrombosis and embolism in patients at high risk of their occurrence. Thrombosis and embolism can occur in many diseases, such as myocardial infarction, stroke, deep venous thrombosis, pulmonary embolism, cancer, etc. Klivarin helps prevent the formation of blood clots and embolisms, which reduces the risk of complications and mortality.

Contraindications and restrictions for use

Clivarin is not recommended for patients with a history of hypersensitivity to reviparin sodium, thrombocytopenia and a documented positive in vitro aggregation test with reviparin sodium. Also, the drug is not prescribed to patients with increased bleeding of wounds, a tendency to bleeding (hemophilia, subdural hematoma, traumatic brain injury, intracranial hemorrhage), bacterial endocarditis, acute erosive and ulcerative lesions of the gastrointestinal tract, threatened miscarriage and in the first trimester of pregnancy.

Clivarin should be used with caution in patients with severe hypertension, retinopathy, severe dysfunction of the liver, kidneys and pancreas, recent cerebrovascular lesions, recent brain surgery or trauma, peptic ulcer of the stomach and duodenum. During long-term treatment, it is necessary to monitor the number of platelets in the blood.

Side effects and interactions with other medications

When using Clivarin, bleeding may occur in case of overdose. General and local allergic reactions, hematomas at the site of subcutaneous administration, thrombocytopenia (reversible and protracted, requiring cessation of treatment), secondary hypoaldosteronism, accompanied by acidosis and hyperkalemia, may also appear.

Clivarin may interact with other medications, such as aspirin, non-steroidal anti-inflammatory drugs, heparin, ticlopidine, clofibrate, antibiotics, anticoagulants, etc. Before starting treatment, you should always consult your doctor and report all medications you are taking to avoid possible interactions.

Dosage and method of administration

The dosage of Clivarin depends on the individual characteristics of the patient and is prescribed by the doctor. Usually the drug is injected subcutaneously at a dose of 20-40 mg once a day. The duration of treatment is determined by the doctor and can range from several days to several months.

In conclusion, Klivarin is an effective drug for the prevention of thrombosis and embolism in patients at high risk of their occurrence. However, it has a number of contraindications and restrictions for use, and can also cause side effects. Before starting treatment, you should definitely consult your doctor.